Busse, Kristin H PharmD*; Hadigan, Colleen MD†; Chairez, Cheryl RN†; Alfaro, Raul M MS*; Formentini, Elizabeth RN‡; Kovacs, Joseph A MD‡; Penzak, Scott R PharmD*
Dyslipidemia continues to be common in HIV-infected individuals.1 The natural history of HIV infection is characterized by decreased levels of total, low-density lipoprotein (LDL), and high-density lipoprotein cholesterol as well as increased triglyceride levels.2 In addition to dyslipidemia associated with HIV infection, the HIV protease inhibitors have been associated with elevations in LDL, total cholesterol, and triglyceride levels.2 The nucleoside reverse transcriptase inhibitor stavudine has been associated with lipid perturbations as well.3 The overall prevalence of hyperlipidemia disorders in patients receiving protease inhibitor-containing highly active antiretroviral therapy (HAART) has been estimated at 27% to 57% and increases with duration of therapy.4 As a result, cardiovascular complications are now being reported in this population.5,6
In addition to cardiovascular disease, HIV-infected individuals whose lipid profiles are marked by significant hypertriglyceridemia (greater than 1000 mg/dL) may be at risk for the development of pancreatitis.1,7 These individuals are often treated with a fibric acid derivative (fibrate) such as gemfibrozil alone or in combination with an HMG-CoA reductase inhibitor (statin) medication.7 However, gemfibrozil alone or in combination with a statin frequently fails to reduce triglyceride concentrations to normal levels.8-10 In addition, a recent study in over 7000 subjects showed that HIV-infected patients who began gemfibrozil therapy had substantially smaller decreases in triglyceride levels compared with non-HIV-infected individuals (44.2% versus 59.3%; P < 0.001).11 Persisting hyperlipidemia (including hypertriglyceridemia) in HIV-infected patients receiving lipid-lowering therapy may be the result of the complex and multifactorial nature of lipid abnormalities in patients with HIV infection.12 An unexplored possibility is that a drug interaction exists between gemfibrozil and one or more antiretroviral medications and that this interaction contributes to gemfibrozil's frequent inability to normalize triglyceride concentrations in HIV-infected HAART recipients.
After near complete oral absorption (oral bioavailability ≅ 100%), gemfibrozil undergoes hepatic metabolism by several pathways.13-15 Oxidation of a ring methyl group forms a hydroxyl methyl and carboxyl metabolite.14,15 There is a paucity of information regarding which enzymes are involved in these oxidative processes.14 Gemfibrozil also undergoes glucuronide conjugation primarily by uridine 5′-diphosphate glucuronosyltransferase isoenzyme (UGT) 2B7.16 Approximately 70% of the drug and its metabolites are excreted in the urine as glucuronide conjugates.14 UGT2B7 is also involved in the metabolism of the anticonvulsants valproic acid and lamotrigine,17,18 both of whose plasma concentrations may be reduced by approximately 50% in the presence of the protease inhibitor combination lopinavir-ritonavir.19,20 If lopinavir-ritonavir reduces gemfibrozil plasma concentrations by a similar magnitude, this may partially explain why triglyceride concentrations frequently fail to normalize in HIV-infected patients receiving gemfibrozil and concurrent lopinavir-ritonavir-containing HAART. As a result of the potentially serious consequences of inadequately treated hypertriglyceridemia, we examined the influence of lopinavir-ritonavir administration for 2 weeks on gemfibrozil pharmacokinetics in healthy human volunteers.
The study population consisted of 15 HIV-negative individuals receiving no other concomitant medications (including prescription, over-the-counter, or herbal preparations) for at least 30 days before and throughout study participation. To be included in the current study, subjects were required to be 18 to 50 years of age, test HIV-negative (enzyme-linked immunosorbent assay), and be free of concurrent illnesses per medical history, physical examination, and screening laboratory values. Screening laboratory values were required to be within institutional normal ranges, except for fasting total cholesterol and triglycerides, which were each required to be below 270 mg/dL. Females of childbearing potential were required to have a negative serum pregnancy test within 7 days of beginning lopinavir-ritonavir and to practice abstinence or use effective nonhormonal methods of birth control during the study. Subjects were required to be nonsmoking for at least 6 weeks before study participation and to refrain from smoking during the entire study period. In addition, subjects were not permitted to ingest fruit juices (grapefruit juice, orange juice, apple juice, and so on) during the course of the investigation.
All participants gave written informed consent, and clinical research was conducted according to guidelines for human experimentation as specified by the US Department of Health and Human Services. This study was approved by the National Institute of Allergy and Infectious Diseases Institutional Review Board.
Study Design and Treatments
This study was conducted as an open-label, single-series design in an outpatient HIV clinic. In each subject, the gemfibrozil pharmacokinetic profile on study Day 1 served as the “control arm” of the study; it was compared with the gemfibrozil pharmacokinetic profile on Day 14 of lopinavir-ritonavir dosing. Any changes in gemfibrozil pharmacokinetics observed in subjects were attributable to the coadministration of lopinavir-ritonavir. Because ritonavir is no longer used as a single protease inhibitor in clinical practice, our study aim was to document the clinical relevance of lopinavir-ritonavir causing any modulation of gemfibrozil pharmacokinetics. Lopinavir-ritonavir was chosen for use in this study given its status as a one of the preferred protease inhibitor combinations recommended for the treatment of HIV in antiretroviral treatment-naïve individuals.21
After an overnight fast, subjects took a single 600-mg gemfibrozil tablet (Teva Pharmaceuticals, North Wales, PA) with 240 mL of water and waited 30 minutes before receiving a standard light breakfast. Blood samples for determination of gemfibrozil plasma concentrations were collected into heparinized tubes at time 0 (predose), 1, 1.5, 2, 3, 4, 6, 8, 12, and 24 hours after the dose. Blood was centrifuged after collection and plasma was harvested and frozen at -80°C until the time of analysis.
After gemfibrozil pharmacokinetic sampling, subjects were allowed a 1-5 week leeway period before starting lopinavir-ritonavir (Kaletra; Abbott Laboratories, North Chicago, IL) 400/100 mg (given as two 200/50-mg tablets) twice daily with food continuing for 14.5 days. This extended leeway period was incorporated into the protocol in an attempt to avoid conflicts with subjects' schedules. However, in actuality, the median time between gemfibrozil pharmacokinetic sampling and the start of lopinavir-ritonavir dosing was 8 days (range, 8-15 days). To monitor adherence, a pill count was conducted before dispensing the medication and when subjects returned for their second pharmacokinetic sampling period. On Day 14 of lopinavir-ritonavir administration, subjects took their morning lopinavir-ritonavir dose with a light breakfast 30 minutes after receiving 600 mg gemfibrozil, and they took their evening lopinavir-ritonavir dose in the usual manner. Blood was drawn for pharmacokinetic sampling of gemfibrozil as on Day 1; additional blood was drawn for laboratory safety monitoring.
Using a newly developed high-performance liquid chromatography method in our laboratory, gemfibrozil and clofibric acid internal standards were separated and detected by tandem mass spectrometry using multiple reaction monitoring. The separation was performed on an Acquity BEH RP18, 2.1 × 50 mm, 1.7-μm analytical column preceded by an Vanguard BEH RP18, 2.1 × 5 mm, 1.7-μm precolumn (Waters Corp., Milford, MA) using a mobile phase gradient starting with a 50:50 (v/v) mixture of acetonitrile and 5.0 mM ammonium formate (buffer) adjusted to pH 3.0 with formic acid at a flow rate of 0.300 ml/min. Gemfibrozil and clofibric acid internal standard were isolated from human plasma by an offline solid-phase extraction method using Oasis MAX 1 ml/30-mg cartridges (Waters Corp.).
Calibration curves for gemfibrozil were linear from 0.020 μg/mL to 20.0 μg/mL with R2 greater than 0.998. Percent errors, as a measure of accuracy, were less than 15% and the inter- and intra-assay coefficients of variation for gemfibrozil were 3.6% to 5.1% and 2.1% to 5.3%, respectively, at three different drug concentrations. The limit of quantitation for gemfibrozil was 0.020 μg/mL and the limit of detection was 0.010 μg/mL.
Gemfibrozil pharmacokinetic parameters were determined using noncompartmental methods with the WinNonlin Professional computer program (Version 5.0; Pharsight Corporation, Mountain View, CA). Maximum plasma concentrations (Cmax) and time to reach Cmax were determined by visual inspection of the concentration-time profiles. The elimination rate constant (λz) was estimated as the absolute value of the slope of a linear regression of a natural logarithm of concentration versus time using at least three points on the line. Half-life was calculated as ln2/λz. Area under the concentration versus time curve (AUC) from 0 hours to the last quantifiable concentration (AUC0-last) was determined using the linear trapezoidal rule. AUC from time 0 to infinity (AUC0-∞) was determined by dividing the last measured concentration by the elimination rate constant (λz) and adding this value to AUC0-last. Apparent oral clearance (CL/F) was estimated as dose divided by AUC0-∞ and apparent volume of distribution (V/F) was estimated as dose divided by the product of AUC0-∞ and λz.
Sample size was calculated with regard to reported variability in gemfibrozil area under the concentration versus time curve (AUC) in healthy volunteers (75 μg/hr/mL with a relative standard deviation of 35%).22 Based on these data and α = 0.05, a sample size of 13 yielded 81% power to detect a clinically relevant change of 30% in gemfibrozil AUC with concomitant lopinavir-ritonavir. Gemfibrozil pharmacokinetic parameters derived pre- and postlopinavir-ritonavir exposure (Days 1 and 14, respectively) were compared using a paired Student t test. Statistical significance was defined a priori as α < 0.05 (SYSTAT Software, Version 11; Richmond, CA).
Fifteen subjects (eight males) screened for and completed the study. The average age and weight of the study participants was 37 (±10) years and 78 (±18) kg, respectively. Gemfibrozil geometric mean pharmacokinetic parameter values and geometric mean ratios (GMRs) are displayed in Table 1. Gemfibrozil AUC0-∞ and Cmax were significantly decreased with lopinavir-ritonavir (Fig. 1). All 15 study subjects experienced a decrease in gemfibrozil AUC0-∞ (GMRs ranged from 0.26 to 0.94 for AUC0-∞), and 12 of 15 subjects experienced a decrease in gemfibrozil Cmax (GMRs ranged from 0.35 to 2.12 for Cmax) with the addition of lopinavir-ritonavir. Gemfibrozil Cl/F and V/F were each significantly increased by 69% after lopinavir-ritonavir (Table 1); this increase was observed in all 15 subjects for Cl/F, in which GMRs ranged from 1.06 to 3.83, and in 12 of 15 subjects for V/F, in which GMRs ranged from 0.76 to 5.20. Gemfibrozil time to reach Cmax and half-life were not significantly changed by lopinavir-ritonavir (Table 1).
All study drugs were generally well tolerated and no subjects withdrew participation. Side effects associated with lopinavir-ritonavir dosing included mainly Grade 1 nausea and diarrhea. As expected, lopinavir-ritonavir was associated with increases in total cholesterol, triglycerides, and LDL cholesterol compared with baseline. Mean triglycerides increased 73% from 77 mg/dL (prelopinavir-ritonavir) to 133 mg/dL (postlopinavir-ritonavir); elevations in total cholesterol and LDL cholesterol were less marked at +8% (177-191 mg/mL) and +11% (110-122 mg/dL), respectively. No additional laboratory abnormalities were observed.
Gemfibrozil pharmacokinetic parameters in this study were not entirely consistent with those previously reported in patients with normal renal function.23,24 We believe this is the result of the sensitivity of our high-performance liquid chromatography/mass spectrometry assay (limit of quantitation = 0.020 μg/mL), which allowed us to measure gemfibrozil plasma concentrations 24 hours postdose. In comparison, previous studies used a less sensitive high-performance liquid chromatography assay (limit of quantitation = 1.0 μg/mL) and were thus limited to 12-hour sampling.23-25 As a result of extended sampling, we were able to characterize the slower terminal elimination phase of gemfibrozil and thus observed an average gemfibrozil half-life of 4.4 hours compared with 1 to 2 hours reported in previous studies that truncated postdose sampling at 12 hours. This increase in half-life we noted (ie, reduction in λz) likely contributed to the increase in apparent V/F we observed compared with previously reported values (37 L versus approximately 10 L for a 70-kg individual) because V/F was estimated as dose divided by the product of AUC0-∞ and λz.26
In this study, 2 weeks of lopinavir-ritonavir administration resulted in a 41% decrease in gemfibrozil AUC0-∞. As a result of the fact that a defined dose-response relationship exists between gemfibrozil and its ability to reduce triglyceride concentrations, the magnitude of the interaction we observed between lopinavir-ritonavir and gemfibrozil is likely to be clinically relevant.27 At approved doses (600 mg twice daily), HIV-negative patients can typically expect triglyceride reductions of 40% to 50% after 3 to 5 months of treatment with gemfibrozil.28-30 When gemfibrozil was administered at 50% of its standard daily dose (600 mg once daily) to 10 HIV-negative individuals with hypertriglyceridemia, the average reduction in triglyceride concentrations was only 16% (range, -34% to +14%) after 9 weeks of therapy.27 Because gemfibrozil displays linear pharmacokinetics,25 a 50% reduction in the daily gemfibrozil dose (600 mg once daily) would be expected to produce an approximate 50% reduction in the drug's AUC, which is similar in magnitude to the 41% reduction in gemfibrozil AUC with lopinavir-ritonavir. These data are consistent with studies that show suboptimal reductions in triglyceride levels in HIV-infected patients receiving protease inhibitor-containing HAART.8-11
The precise mechanism of the interaction between gemfibrozil and lopinavir-ritonavir cannot be determined from our study. The influence of lopinavir-ritonavir on gemfibrozil pharmacokinetics, which is hallmarked by reductions in gemfibrozil AUC and Cmax without a subsequent change in half-life, does not appear to be the result of induction of hepatic (or intestinal) UGT2B7 or gemfibrozil oxidation by lopinavir-ritonavir, because these enzymatic processes do not exhibit an appreciable first-pass effect on gemfibrozil pharmacokinetics.13,14 Alternatively, one would expect induction of gemfibrozil metabolism through glucuronidation or oxidation to primarily alter (reduce) the half-life of the drug, which we did not observe.
Instead, lopinavir-ritonavir appeared to produce a significant reduction in gemfibrozil bioavailability (F); this is supported by the significant (and similar) reductions observed in gemfibrozil Cmax and AUC with lopinavir-ritonavir and by the fact that gemfibrozil apparent oral clearance (CL/F) and apparent V/F increased to an identical extent with the addition of lopinavir-ritonavir (ie, a similar reduction in F would result in similarly increased estimations of apparent oral clearance and volume).
A potential mechanism for the apparent decrease in gemfibrozil absorption with concurrent lopinavir-ritonavir is modulation of presystemic gemfibrozil transport by lopinavir-ritonavir; unfortunately, little information is available regarding which enterocyte proteins are involved in the intestinal transport of gemfibrozil. Hepatic organic anion transport polypeptide 1B1 (OATP1B1) may be inhibited by lopinavir-ritonavir31; however, hepatic inhibition of OATP1B1 would be expected to produce an increase in gemfibrozil exposure assuming that gemfibrozil, itself an inhibitor of OATP1B1,32 is also an OATP1B1 substrate. Originally thought to be liver-specific, OATP1B1 is also expressed in the intestine.33 Inhibition of OATP1B1 in the intestinal tract by lopinavir-ritonavir could theoretically reduce gemfibrozil absorption (again, assuming gemfibrozil is an OATP1B1 substrate); however, the role of OATP1B1 in the intestine is questionable because it was incapable of transporting the common OATP substrate, fexofenadine.33 To this end, further study is necessary to elucidate gemfibrozil transport in vivo to determine the mechanism by which lopinavir-ritonavir reduced the systemic availability of gemfibrozil.
An additional point for consideration is the possibility that gemfibrozil, which is 98.6% bound to albumin in plasma, underwent significant protein binding displacement when combined with lopinavir-ritonavir.34 This could potentially result in a transient increase in free (unbound) gemfibrozil concentrations that subsequently return to preinteraction levels. As a result, total (bound plus unbound drug) gemfibrozil concentrations would be expected to decrease without a noticeable change in the drug's half-life; such a scenario would be consistent with our findings. Because unbound (pharmacologically active) gemfibrozil concentrations would be unaltered in this case, dosage increases to compensate for reduced gemfibrozil exposure would be inappropriate. However, both lopinavir and ritonavir have a higher binding affinity for alpha-1 acid glycoprotein (to which gemfibrozil does not bind) versus albumin,35,36 perhaps making this scenario less likely. Moreover, ritonavir displaces other highly protein bound drugs only to a small degree, even at higher concentrations (5 mg/L), than those achieved when the drug is administered at boosting doses of 100 mg twice daily (≅0.5 mg/L).36,37
Although the precise mechanism of the interaction between lopinavir-ritonavir and gemfibrozil is unknown, a more imminent concern for clinicians is how this interaction should be managed in the clinical setting. The first option would be to avoid lopinavir-ritonavir, but this may not be practical or feasible for many patients, particularly if one chooses to avoid all ritonavir-containing regimens based on the assumption that ritonavir is the culpable agent in the interaction between gemfibrozil and lopinavir-ritonavir. Another approach to avoiding this interaction might involve substituting gemfibrozil with another triglyceride-lowering agent such as fenofibrate. However, given fenofibrate's chemical similarity to gemfibrozil (both are fibric acid derivatives), an interaction with ritonavir and/or lopinavir-ritonavir cannot be ruled out. Statins could be used as an alternative, or in addition to, gemfibrozil; however, statins are more effective in reducing cholesterol than triglycerides, and again clinical experience suggests that they are relatively ineffective in lowering the latter.7 Moreover, serious drug interactions between certain statins and protease inhibitors are well described.7 Another option is to increase the gemfibrozil dose, but as a result of the unknown risks of increased gemfibrozil exposure (elevated creatinine kinase, rhabdomyolysis, and so on), this approach should be initiated within the controlled environment of a clinical trial.
In conclusion, results from this investigation offer clear evidence of a potentially significant drug-drug interaction between gemfibrozil and lopinavir-ritonavir. However, further study is necessary to characterize the specific oxidative pathways of gemfibrozil, to identify transport proteins involved in gemfibrozil uptake and/or efflux at the intestinal and hepatic levels, and to characterize the influence of lopinavir-ritonavir on the formation of gemfibrozil's various oxidative and glucuronide metabolites. Once collected, this information should shed light on the precise mechanism by which lopinavir-ritonavir interacts with gemfibrozil and provide helpful information for clinicians managing this interaction in the clinical setting.
1. Dube MP, Stein JH, Aberg JA, et al. Guidelines for the evaluation and management of dyslipidemia in human immunodeficiency virus (HIV)- infected adults receiving antiretroviral therapy: recommendations of the HIV medicine association of the Infectious Disease Society of America and the Adult AIDS Clinical Trials Group. Clin Infect Dis
2. Kamin DS, Grinspoon SK. Cardiovascular disease in HIV-positive patients. AIDS
3. Jones R, Sawleshwarkar S, Michailidis C, et al. Impact of antiretroviral choice on hypercholesterolaemia events: the role of the nucleoside reverse transcriptase inhibitor backbone. HIV Med
4. Grinspoon S, Carr A. Cardiovascular risk and body-fat abnormalities in HIV-infected adults. N Engl J Med
5. Kaplan RC, Kingsley LA, Sharrett AR, et al. Ten-year predicted coronary heart disease risk in HIV-infected men and women. Clin Infect Dis
6. DAD Study Group, Friis-Moller N, et al. Class of antiretroviral drugs and the risk of myocardial infarction. N Engl J Med
7. Penzak SR, Chuck SK. Management of protease inhibitor-associated hyperlipidemia. Am J Cardiovasc Drugs
8. Miller J, Brown D, Amin J, et al. A randomized, double-blind study of gemfibrozil for the treatment of protease inhibitor-associated hypertriglyceridaemia. AIDS
9. Hewitt RG, Shelton MJ, Esch LD. Gemfibrozil effectively lowers protease inhibitor-associated hypertriglyceridemia in HIV-1-positive patients. AIDS
10. Henry K, Melroe H, Huebesch J, et al. Atorvastatin and gemfibrozil for protease-inhibitor-related lipid abnormalities. Lancet
11. Silverberg MJ, Leyden W, Hurley L. Response to newly prescribed lipid-lowering therapy in patients with and without HIV infection. Ann Intern Med
12. Pao V, Lee GA, Grunfeld C. HIV therapy, metabolic syndrome, and cardiovascular risk. Curr Atheroscler Rep
13. Miller DB, Spence JD. Clinical pharmacokinetics of fibric acid derivatives (fibrates). Clin Pharmacokinet
14. Spence JD. Metabolism of fibric acid derivatives. Clin Pharmacokinet
15. Lopid [package insert]. New York, NY: Pfizer; Sept 2006.
16. Mano Y, Usui T, Kamimura H. The UDP-glucuronosyltransferase 2B7 isozyme is responsible for gemfibrozil glucuronidation in the human liver. Drug Metab Dispos
17. Rowland A, Elliot DJ, Williams JA, et al. In vitro characterization of lamotrigine N2-glucuronidation and the lamotrigine-valproic acid interaction. Drug Metab Dispos
18. Argikar UA, Remmel RP. Effect of aging on glucuronidation of valproic acid in human liver microsomes and the role of UGT1A4, UGT1A8 and UGT1A10. Drug Metab Dispos
. 2008 Oct 6 [Epub ahead of print].
19. van der Lee MJ, Dawood L, Hadewych JM. Lopinavir/ritonavir reduces lamotrigine plasma concentrations in healthy subjects. Clin Pharmacol Ther
20. Sheehan NL, Brouillette MJ, Delisle MS, et al. Possible interaction between lopinavir/ritonavir and valproic acid exacerbates bipolar disorder. Ann Pharmacother
21. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services. January 29, 2008:1-128. Available at: www.aidsinfo.nih.gov/ContentFiles/AdultandAdolescentGL.pdf
. Accessed October 10, 2008.
22. Spence JD, Munoz CE, Hendricks L, et al. Pharmacokinetics of the combination of fluvastatin and gemfibrozil. Am J Cardiol
23. Forland SC, Feng Y, Cutler RE. Apparent reduced absorption of gemfibrozil when given with colestipol. J Clin Pharmacol
24. Evans JR, Forland SC, Cutler RE. The effect of renal function on the pharmacokinetics of gemfibrozil. J Clin Pharmacol
25. Forland SC, Chaplin L, Cutler RE. Assay of gemfibrozil in plasma by ‘high performance’ liquid chromatography. Clin Chem
26. Todd PA, Ward A. Gemfibrozil a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in dyslipidemia. Drugs
27. de Salcedo I, Gorringe AL, Silva JL, et al. Gemfibrozil in a group of diabetics. Proc Roy Soc Med
28. Cortese C, Abate G, Averna M, et al. An open label multicenter study to evaluate the efficacy and tolerability of gemfibrozil in elderly hyperlipidemic patients. Nutr Metab Cardiovasc Dis
29. Kaukola S, Manninen V, Mälkönen M, et al. Gemfibrozil in the treatment of dyslipidaemias in middle-aged male survivors of myocardial infarction. Acta Med Scand
30. Mussoni L, Mannucci L, Sirtori C, et al. Effects of gemfibrozil on insulin sensitivity and on haemostatic variables in hypertriglyceridemic patients. Atherosclerosis
31. Kiser JJ, Gerber JG, Predhomme JA, et al. Drug/drug interaction between lopinavir-ritonavir and rosuvastatin in healthy volunteers. J Acquir Immune Defic Syndr
32. Nakagomi-Hagihara R, Nakai D, Tokui T, et al. Gemfibrozil and its glucuronide inhibit the hepatic uptake of pravastatin mediated by OATP1B1. Xenobiotica
33. Glaeser H, Bailey DG, Dresser GK, et al. Intestinal drug transporter expression and the impact of grapefruit juice in humans. Clin Pharmacol Ther
34. Hamberger C, Barre J, Zini R, et al. In vitro binding study of gemfibrozil to human serum proteins and erythrocytes: interactions with other drugs. Int J Clin Pharmacol Res
35. Kaletra [package insert]. North Chicago, IL: Abbott Laboratories; Oct 2008.
36. Hsu A, Granneman GR, Bertz RJ. Ritonavir: clinical pharmacokinetics and interactions with other anti-HIV agents. Clin Pharmacokinet
37. Lim ML, Min SS, Eron JJ, et al. Coadministration of lopinavir/ritonavir and phenytoin results in two-way drug interaction through cytochrome P-450 induction. J Acquir Immune Defic Syndr
© 2009 Lippincott Williams & Wilkins, Inc.